Parse Biosciences and Codebreaker Labs launched a collaboration to combine Codebreaker’s engineered variant libraries with Parse’s single‑cell transcriptomics platform to experimentally map how genetic variants alter cellular states. The partnership aims to generate functional datasets to inform whole‑genome interpretation, target discovery, AI model training, and precision trial design. The deal follows Parse’s broader efforts, including a collaboration with Tahoe Therapeutics to create a 300‑million single‑cell perturbation dataset. Qiagen’s pending acquisition of Parse (up to $280 million) contextualizes the platform’s industry momentum. Large-scale empirical mapping of variant effects at single‑cell resolution could accelerate validation of rare variants and feed machine learning models used by drug discovery teams and regulatory submissions.